Background: After potentially curative resection of primary colorectal cancer, patients may be monitored by measurement of carcinoembryonic antigen and/or CT to detect asymptomatic metastatic disease earlier.
Introduction
A variety of monitoring strategies have been used in patients who have had potentially curative surgery for primary colorectal cancer. Their aim has been to detect active disease before it is symptomatic or clinically evident so that further treatment can be instigated. Five randomized trials published from 1995 to 1998 were the subject of a systematic review and meta-analysis published in 2002 1 . Intensive follow-up was associated with significantly earlier detection by a mean of 8⋅5 months. The combined risk ratio was 0⋅81 (95 per cent c.i. 0⋅70 to 0⋅94) in favour of intensive follow-up. However, the authors found that methods were poorly reported and concluded that 'large trials are required to identify which components of intensive follow up are most beneficial'. Since then, three large trials 2 -4 of intensified monitoring have reported. An updated search, systematic review and meta-analysis have been undertaken to examine the effect of these programmes on overall survival including all randomized studies identified.
Methods
A systematic review of literature on follow-up strategies for patients with colorectal cancer was conducted according to the PRISMA guidelines 5 and is registered in PROSPERO (CRD42015026835). This study was based on predefined eligibility criteria and conducted according to a predefined methodological approach.
Search strategy
An extensive search for published articles was conducted in collaboration with a medical librarian. The electronic databases of MEDLINE (Ovid), Embase, the Cochrane Library and Web of Science, Scopus, CINAHL (EBSCO), PubMed publisher, Google Scholar, LILACS, SciELO and ProQuest were searched. The searches identified four index terms: large intestinal cancer, surgery, periodical surveillance and mortality or survival. Appropriate thesaurus terms (for MEDLINE, Embase and CINAHL) and keywords in the title and/or abstract were combined by Boolean logical operators, and adapted to the appropriate syntax of each database. The reference lists of reviews and included studies were cross-checked.
Selection of studies
Papers were screened by two independent investigators, arbitrated by a third reviewer. Data were extracted from studies reporting randomly assigned groups of patients in surveillance protocols of differing intensity. Only studies conducted in humans and written in English were included. Studies with inadequate data on survival for meta-analysis were retained for textual summaries of the design, findings and conclusions.
Outcome measures
The primary outcome was the overall survival difference between the existing monitoring strategy compared with a more intensive monitoring strategy.
Quality control
Studies were checked independently for quality using the Cochrane risk of bias tool 6 . The authors of all studies were approached for further information 7 .
Data extraction
Data were extracted by one researcher and checked independently by a second reviewer. A third investigator resolved any discrepancies. Patient numbers, baseline characteristics, all-cause mortality, cancer-specific mortality and recurrence rates were retrieved for each study.
Potentially relevant studies n = 13 987
Duplicates excluded n = 6906
Articles for title/abstract screening n = 7081
Excluded n = 7059 No colorectal cancer n = 3067 Other aspects of colorectal cancer n = 2758 Case report n = 500 Opinion/review n = 324 Retrospective study n = 123 Other language n = 110 Conference/guidelines n = 109 Before 1980 n = 68
Articles for full-text screening n = 22 papers n = 16 trials Overall survival data were extracted as event rates reported for more versus less intensive monitoring arms of all randomized comparisons. Odds ratios (ORs) and their variances were calculated. Hazard ratios (HRs) were derived from Kaplan-Meier curves. The method described by Williamson and colleagues 8 was used to estimate a logarithmic HR with corresponding variance when the number of patients at risk was given at each time point. If these data were not provided, the method of Parmar et al. 9 was used. The overall HR with 95 per cent c.i. was estimated using an inverse variance-weighted average 10 .
Statistical analysis
Review Manager (RevMan) for Windows ® version 5.3 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) was used for meta-analysis. Funnel plots were used to investigate publication bias. Heterogeneity among the included studies was analysed by means of the I 2 measure 11 . A random-effects meta-analysis was performed after exclusion of trials with a high risk of bias.
ORs were also used to summarize observed effects, and a random-effects logistic regression model was used to provide an overall estimate of an effect for subsets of studies defined by the chosen method of enhanced detection. Subgroup analyses of outcome were performed to account for different diagnostic tests used during follow-up in different randomized trials. Studies were grouped as follows: any site of recurrence; endoscopically detected recurrence; or CT *There were more tests, more frequent tests, or both in the group with more intensive monitoring. †If the carcinoembryonic antigen (CEA) level was raised according to study criteria, patients were randomized to have this revealed to the clinical team or not.
the clinical setting of follow-up. Sensitivity analyses were performed to identify studies that were estimated to have a high risk of bias. Meta-analysis was undertaken and forest plots were constructed for all trials that reached the criteria for inclusion. Since the previous meta-analysis calling for large trials 1 , there have been three large multicentre trials, published in 2006, 2014 and 2016 2 -4 relating to policies of earlier detection of patients suitable for the growing practice of metastasectomy 12 -14 . The analysis was repeated in this subset of trials.
Results
Among 7081 publications, there were 22 relevant articles 2 -4,15-33 describing 16 randomized comparisons ( Fig. 1) . Text summaries of all 16 randomized trials are provided in Appendix S1 (supporting information). Five studies were excluded because there were no survival data available for analysis 28, 31 or they had high risk of bias 18, 21, 23 ( Table 1) . The remaining 11 studies provided data on overall survival suitable for meta-analysis and, of these, seven 2 Ohlsson et al. 17 Pietra et al. 22 Mäkelä et al. 16 Rodriguez
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of metastases ( Table 2 , Figs 2 and 3) . Two studies 20, 27 were confined to endoscopic examination following more or less intensive protocols ( Table 3) . Two studies 24, 25 followed the same protocol in each arm but were administered in hospital by a specialist or in a general practice setting. Detailed protocols for investigations used for monitoring and their frequency are summarized in Appendix S2 (supporting information).
Quality of studies: risk of bias
Three studies were found to have a high risk of bias in at least one domain ( Table 4 ). Blinding of participants and personnel (performance bias) was not possible and so there is a remaining risk of bias. Blinding of outcome assessment (detection bias) is not relevant for the main outcome measure, which is death/survival.
Effectiveness of more intensive monitoring in advancing detection
For studies in which the time difference in detection was given (9 of 16) the advance in diagnosis was 2-30 months, with a median of 10 (i.q.r. 5-24) months ( 24 Augestad et al. 26 25 Odds ratio Fig. 4 Forest plot for death in two studies in which the difference in monitoring was confined to endoscopy, and two studies for which the difference was between a hospital/specialist setting and a general practice setting. A Mantel-Haenszel random-effects model was used to produce an overall estimated odds ratio. Odds ratios are shown with 95 per cent confidence intervals 
Main outcome measure: effectiveness in improving survival
The numbers of randomized patients and the numbers of all detection events and deaths are given in Tables 6 -8 . The principal result derives from the meta-analysis of HRs based on trials from which these could be estimated. The summary HR estimate was 0⋅98 (95 per cent c.i. 0⋅87 to 1⋅11), with no evidence of significant heterogeneity (I 2 = 14 per cent) (Fig. 2) .
The meta-analysis of simple ORs for death based on the same seven studies is shown in Fig. 3 ; the summary OR for death was 0⋅91 (95 per cent c.i. 0⋅71 to 1⋅16). ORs were derived from the percentage of deaths in each arm at the time of reporting, whereas the HR gives an estimate of the overall relative survival, which is more relevant when considering a time-to-event endpoint.
A meta-analysis of ORs for death is also shown for two studies in which the difference in monitoring was confined to endoscopy, and two studies for which the difference was between a hospital/specialist setting and a general practice setting (Fig. 4) .
There is a residual possibility of publication bias as demonstrated in the asymmetry of the forest plot for the main analysis (Fig. 2) and the funnel plot (Fig. 5) . Because of the proportion of the weight accredited by RevMan to CEASL (Carcino-Embryonic Antigen Second Look), and because in this study the monitoring was solely by CEA and not CT, a sensitivity analysis was performed after exclusion of CEASL. This did not alter the conclusion (HR 0⋅92, 0⋅76 to 1⋅36)
The three trials reporting from 2006 to 2016 were larger, multicentre, better quality studies and contributed 2689 (80⋅9 per cent) of the 3325 patients included in the overall meta-analysis (Fig. 2) . The summary estimated HR from a meta-analysis of these trials was 1⋅05 (0⋅87 to 1⋅27) (Fig. 6) .
Discussion
The question addressed by this systematic review is whether follow-up strategies involving more intensive monitoring, with more frequent investigation and/or additional methods of detection, lead to an improvement in overall survival. Meta-analyses of the ORs and derived HRs from seven RCTs including 3325 patients showed no survival benefit from successively intensified monitoring policies. The authors of ten 2 -4,16,17,20,24,25,27,30 of the 11 trials reported no survival benefit from more intensive monitoring. This could have been due to lack of power, but the meta-analysis is consistent with the findings of individual studies. Three studies 4, 24, 26 that reported outcomes on quality of life found no differences with respect to this outcome.
A random-effects model and, where possible, HRs were used to quantify outcomes, as the outcomes of interest occur over time. Owing to data limitations, ORs were used for some comparisons. Where it was possible to do both analyses, there was no difference in the conclusion. A limitation of this systematic review is that publication bias may have affected the observed outcomes as unpublished data, abstracts and presentations were not included. However, consideration of this possible bias would likely make a survival benefit even less plausible.
Intensive follow-up was reported to show significantly improved survival by the authors of only one study 22 . It was attributed to reappearance of treatable residual disease after resection of rectal (as opposed to colonic) cancer. In exploratory subset analyses, other studies 2,4 showed a survival difference in favour of more intensive monitoring benefit where local recurrence of rectal cancer was found endoscopically.
Earlier meta-analyses 1,35 suggested a favourable effect on survival. This was not found in the present meta-analysis, which included larger and methodologically more robust trials reported in the past couple of years. These showed poorer survival in the more intensively screened groups, although the results were not significant individually. The survival results of this updated meta-analysis show no benefit. Although not statistically significant, the point estimates consistently suggest an adverse effect on survival. What these later RCTs have in common is that they were multicentre studies run from trial centres. It is possible that the commitment of physicians involved in follow-up has made a difference to outcomes in smaller institutional studies. Many of these patients will have had individualized treatment including systemic chemotherapy, but no overall benefit from monitoring and earlier detection has been shown in the meta-analysis. This analysis gives a coherent and trustworthy, but disappointingly negative, message about the hoped-for survival benefit of intensification of active monitoring after primary resection of colorectal cancer.
Editor's comment
Cancer is a frightening word that brings uncertainty to patients' lives and those of their loved ones. It is our role to dispel fear, establish trust, and deliver realistic expectations for the future. Tests give confidence to both parties if sensitive, specific, and comfortable, as well as cost-effective and generalizable. Clinical assessment, quality colonoscopy, serum carcinoembryonic antigen testing, and baseline CT fulfil all those targets at diagnosis. Repetition of scans every 6-12 months is in doubt if the findings presented here do not represent immortal time bias or other anomaly. If so, then we understand pitifully little of the biological interplay between host and disease that evade the (evidently) crude instruments of this age.
Cancer outcomes improved with specialized surgery, multidisciplinary management, and molecular-targeted therapy, so it is counterintuitive that earlier identification of metastatic disease does not improve survival. Intensive surveillance should prolong disease-specific survival by bringing forward the date of diagnosis and by rendering the disease burden easier to manage. Far from being the bleak nihilism some will choose to see, this paper will stimulate evolution (not cessation) of surveillance and metastasis-directed healthcare. It challenges us to determine how to follow patients optimally, to whom to offer intensive monitoring, and to better define the molecular complexity of tumour-immune interfaces. Fear of the unknown is a burden we have allowed patients to shoulder while we peer over the horizon of their personal voyage. If you are not alarmed that modern colorectal cancer care is suboptimal after reading this paper, please reflect on it again.
D. C. Winter
Editor, BJS 
